Decoding Big Pharmas R&D Strategy in Oncology
Introduction
This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on an analysis of some of the major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, Novartis and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Each of these oncology field leaders are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.
This report focuses on Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five included big pharma companies. The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions.
Decoding Big Pharma’s R&D Strategy in Oncology in numbers:
- Includes references to more than 250 drugs and 600 clinical/preclinical trials
- Addresses the competitive situation on more than 80 different cancer indications, including supportive care indications
- Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer
- The included competitive landscape between the five big pharma includes more than 200 companies related to cancer drug development
- Last five years of deals and alliances in oncology, including almost a hundred different key deals and alliances
- Target analysis of 119 drug targets in oncology, including molecular function of target, target localization, type of compound for targeting, targets affecting signaling pathways etc
- Drug compound analysis by cancer indications
Other users found this report page using the following search terms: oncology oncology rd strategy pharma cost development novartis companies big aventi
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.